Rosh Chandraratna, PhD, MBA, is a co-founder of Io Therapeutics, and currently serves as its president and chief scientific officer. He is the discoverer of IRX4204, the RXR nuclear receptor agonist compound being developed by Io Therapeutics as a potentially disease-modifying treatment for Parkinson’s disease.

Dr. Chandraratna received his PhD in synthetic organic chemistry from Kansas State University, and served as a post-doctoral fellow in synthetic organic medicinal chemistry at the University of California, Riverside. He received an MBA from Pepperdine University.

Dr. Chandraratna has worked for more than 30 years in the fields of drug discovery research and development, with special emphasis on drugs targeting rexinoid and retinoid nuclear receptors. He has served as an officer of several biopharmaceutical companies, including Allergan Pharmaceuticals, where he discovered IRX4204. He is an inventor on over 200 issued US patents, and author of numerous publications in the fields of medicinal chemistry and nuclear receptor pharmacology.